277 related articles for article (PubMed ID: 15688618)
1. New microtubule/tubulin-targeted anticancer drugs and novel chemotherapeutic strategies.
Wilson L; Jordan MA
J Chemother; 2004 Nov; 16 Suppl 4():83-5. PubMed ID: 15688618
[TBL] [Abstract][Full Text] [Related]
2. Bcl-xL is phosphorylated in malignant cells following microtubule disruption.
Poruchynsky MS; Wang EE; Rudin CM; Blagosklonny MV; Fojo T
Cancer Res; 1998 Aug; 58(15):3331-8. PubMed ID: 9699663
[TBL] [Abstract][Full Text] [Related]
3. In vivo measurement of microtubule dynamics using stable isotope labeling with heavy water. Effect of taxanes.
Fanara P; Turner S; Busch R; Killion S; Awada M; Turner H; Mahsut A; Laprade KL; Stark JM; Hellerstein MK
J Biol Chem; 2004 Nov; 279(48):49940-7. PubMed ID: 15385549
[TBL] [Abstract][Full Text] [Related]
4. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
Jordan MA; Horwitz SB; Lobert S; Correia JJ
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
[TBL] [Abstract][Full Text] [Related]
5. Septin filament coalignment with microtubules depends on SEPT9_i1 and tubulin polyglutamylation, and is an early feature of acquired cell resistance to paclitaxel.
Targa B; Klipfel L; Cantaloube I; Salameh J; Benoit B; Poüs C; Baillet A
Cell Death Dis; 2019 Jan; 10(2):54. PubMed ID: 30670682
[TBL] [Abstract][Full Text] [Related]
6. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
Tangutur AD; Kumar D; Krishna KV; Kantevari S
Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
[TBL] [Abstract][Full Text] [Related]
7. Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity.
Sun X; Li D; Yang Y; Ren Y; Li J; Wang Z; Dong B; Liu M; Zhou J
J Pathol; 2012 Mar; 226(4):666-73. PubMed ID: 21989536
[TBL] [Abstract][Full Text] [Related]
8. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
Kowalski RJ; Giannakakou P; Gunasekera SP; Longley RE; Day BW; Hamel E
Mol Pharmacol; 1997 Oct; 52(4):613-22. PubMed ID: 9380024
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of paclitaxel-induced microtubule stabilization, mitotic arrest, and apoptosis by the microtubule-targeting agent EM012.
Zhou J; Liu M; Aneja R; Chandra R; Joshi HC
Biochem Pharmacol; 2004 Dec; 68(12):2435-41. PubMed ID: 15548390
[TBL] [Abstract][Full Text] [Related]
10. Molecular dynamics simulation and free energy landscape methods in probing L215H, L217R and L225M βI-tubulin mutations causing paclitaxel resistance in cancer cells.
Tripathi S; Srivastava G; Sharma A
Biochem Biophys Res Commun; 2016 Aug; 476(4):273-279. PubMed ID: 27233604
[TBL] [Abstract][Full Text] [Related]
11. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4.
Zhang CC; Yang JM; Bash-Babula J; White E; Murphy M; Levine AJ; Hait WN
Cancer Res; 1999 Aug; 59(15):3663-70. PubMed ID: 10446979
[TBL] [Abstract][Full Text] [Related]
12. Effects of novel taxanes SB-T-1213 and IDN5109 on tubulin polymerization and mitosis.
Jordan MA; Ojima I; Rosas F; Distefano M; Wilson L; Scambia G; Ferlini C
Chem Biol; 2002 Jan; 9(1):93-101. PubMed ID: 11841942
[TBL] [Abstract][Full Text] [Related]
13. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death.
Blagosklonny MV; Giannakakou P; el-Deiry WS; Kingston DG; Higgs PI; Neckers L; Fojo T
Cancer Res; 1997 Jan; 57(1):130-5. PubMed ID: 8988053
[TBL] [Abstract][Full Text] [Related]
14. Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.
Wang Y; Yin S; Blade K; Cooper G; Menick DR; Cabral F
Biochemistry; 2006 Jan; 45(1):185-94. PubMed ID: 16388594
[TBL] [Abstract][Full Text] [Related]
15. Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumours to docetaxel.
Veitia R; David S; Barbier P; Vantard M; Gounon P; Bissery MC; Fellous A
Br J Cancer; 2000 Aug; 83(4):544-9. PubMed ID: 10945505
[TBL] [Abstract][Full Text] [Related]
16. Microtubule-associated proteins as targets in cancer chemotherapy.
Bhat KM; Setaluri V
Clin Cancer Res; 2007 May; 13(10):2849-54. PubMed ID: 17504982
[TBL] [Abstract][Full Text] [Related]
17. Microtubule alterations and resistance to tubulin-binding agents (review).
Drukman S; Kavallaris M
Int J Oncol; 2002 Sep; 21(3):621-8. PubMed ID: 12168109
[TBL] [Abstract][Full Text] [Related]
18. Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agents.
Sackett DL; Giannakakou P; Poruchynsky M; Fojo A
Cancer Chemother Pharmacol; 1997; 40(3):228-32. PubMed ID: 9219506
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel resistance in cells with reduced beta-tubulin.
Wang Y; Cabral F
Biochim Biophys Acta; 2005 Jun; 1744(2):245-55. PubMed ID: 15950754
[TBL] [Abstract][Full Text] [Related]
20. Potential mechanisms of resistance to microtubule inhibitors.
Kavallaris M; Annereau JP; Barret JM
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
